Genentech’s income for 1st-qtr climbs 68% to $706M, but market unimpressed
<p class="source">Pharma Marketletter</p>
<p>Genentech's soaring income drew criticism from some quarters, including the Santa Monica-based Foundation for Taxpayer and Consumer rights, which argued that the "outrageous profits came thanks to public funding of Genentech's research."</p>
